BREAKING
PDS Biotechnology Corporation (PDSB) FY 2025 Earnings Recap 16 minutes ago Unicycive Therapeutics, Inc. (UNCY) Reports FY2025 Earnings 24 minutes ago USA Rare Earth, Inc. (USAR) Reports Q4 Earnings 27 minutes ago Bicara Therapeutics 2025 Financial Update 40 minutes ago PDS Biotechnology Corporation (PDSB) Reports FY2025 Earnings 54 minutes ago Neumora Therapeutics 2025 Financial Update 1 hour ago Americas Gold and Silver Corporation (USAS) Misses FY2025 EPS Estimates by 425.0% 1 hour ago CBAK Energy Technology, Inc. (CBAT) Reports FY2025 Earnings 2 hours ago Reviva Pharmaceuticals 2025 Financial Review 2 hours ago Southland Holdings, Inc. (SLND) Q4 Earnings: Misses on EPS, Revenue Recap 3 days ago PDS Biotechnology Corporation (PDSB) FY 2025 Earnings Recap 16 minutes ago Unicycive Therapeutics, Inc. (UNCY) Reports FY2025 Earnings 24 minutes ago USA Rare Earth, Inc. (USAR) Reports Q4 Earnings 27 minutes ago Bicara Therapeutics 2025 Financial Update 40 minutes ago PDS Biotechnology Corporation (PDSB) Reports FY2025 Earnings 54 minutes ago Neumora Therapeutics 2025 Financial Update 1 hour ago Americas Gold and Silver Corporation (USAS) Misses FY2025 EPS Estimates by 425.0% 1 hour ago CBAK Energy Technology, Inc. (CBAT) Reports FY2025 Earnings 2 hours ago Reviva Pharmaceuticals 2025 Financial Review 2 hours ago Southland Holdings, Inc. (SLND) Q4 Earnings: Misses on EPS, Revenue Recap 3 days ago
ADVERTISEMENT
Breaking News

USA Rare Earth, Inc. (USAR) Reports Q4 Earnings

USA Rare Earth, Inc.

March 30, 2026 2 min read

USA Rare Earth, Inc.

USARUSAR|EPS -$0.19|Rev $1.6M|Net Loss $50.5M

USA Rare Earth, Inc. reported a loss of $0.19 per share for the fourth quarter of 2025, as the rare earth minerals developer continues to invest heavily in its operations. The company generated $1.6M in revenue for the quarter while posting a net loss of $50.5M for the period.

The substantial quarterly loss reflects the capital-intensive nature of rare earth development and processing operations. USA Rare Earth focuses on securing domestic supply chains for critical minerals used in defense, renewable energy, and technology applications, a sector that typically requires significant upfront investment before reaching commercial-scale production.

Despite the loss, Wall Street maintains a largely positive outlook on the company’s prospects. The analyst consensus stands at 7 buy, 1 hold, 0 sell, suggesting confidence in USA Rare Earth’s strategic positioning within the critical minerals sector. The company operates in an industry that has drawn increased attention from policymakers seeking to reduce reliance on foreign sources of rare earth elements.

The rare earth sector has seen heightened interest as governments worldwide prioritize supply chain security for materials essential to electric vehicles, wind turbines, and military hardware.

A detailed analysis of USA Rare Earth, Inc.’s quarter follows shortly on AlphaStreet.

This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.

ADVERTISEMENT